Importância dos vírus nas exacerbações da Doença Pulmonar Obstrutiva Crônica (DPOC). Poderia mudar seu comportamento durante a pandemia de SARS-COV-2 (COVID-19)?
Resumo
A pandemia de SARS-COV-2 tem gerado muitos questionamentos sobre o comportamento das doenças crônicas. Embora se saiba que pacientes com comorbidades significativas apresentam risco aumentado de complicações, o comportamento de doenças como a doença pulmonar obstrutiva crônica (DPOC) não é conhecido. No período de pandemia e quarentena por COVID-19. Neste artigo, foi realizada uma revisão da literatura sobre os principais aspectos teóricos para compreender as possíveis interações entre a infecção por SARS-COV-2 e pacientes com patologia respiratória, como DPOC. Foram revisados os principais aspectos das infecções virais e sua fisiopatologia na exacerbação da doença, seus mecanismos inflamatórios e as condições que podem aumentar o risco de infecção e gravidade durante a pandemia COVID-19. Além disso, foram explorados aspectos relacionados à quarentena e sua possível influência na exacerbação da doença. Por fim, foram explorados os aspectos econômicos relacionados à exacerbação e sua gestão associada à pandemia.
Downloads
Referências
Guan W, Ni Z, Hu Y, Liang W, P Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. [Internet]. 2020 abr; 382: 1708-120. Disponible en: https://www.nejm.org/doi/full/10.1056/nejmoa2002032 DOI: https://doi.org/10.1056/NEJMoa2002032
Organización Panamericana de la Salud, Organización Mundial de la Salud. Actualización epidemiológica del nuevo coronavirus (covid-19). Washington: OPS, OMS; 2020. Disponible en: https://www.paho.org/sites/default/files/2020-02/2020-feb-14-phe-actualizacion-epi-covid19.pdf
Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. [Internet]. 2019 mar; 17(3): 181-192. Disponible en: https://www.nature.com/articles/s41579-018-0118-9 DOI: https://doi.org/10.1038/s41579-018-0118-9
Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. covid-19 does not lead to a "typical" acute respiratory distress syndrome. Am J Respir Crit Care Med. [Internet]. 2020 may; 201(10): 1299-1300. DOI: https://doi.org/10.1164/rccm.202003-0817LE
Organización Mundial de la Salud. Alocución del director general de la OMS en la rueda de prensa sobre la covid-19 celebrada el 11 de marzo de 2020. [Internet]. Disponible en: https://www.who.int/es/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020
Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with covid-19: evidence from meta-analysis. Aging. [Internet]. 2020 abr; 12(7): 6049-6057. Disponible en: https://www.aging-us.com/article/103000/text DOI: https://doi.org/10.18632/aging.103000
Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with covid-19: a systematic review and meta-analysis. Arch Acad Emerg Med. [Internet]. 2020 mar; 8(1): e35. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096724/ DOI: https://doi.org/10.1371/journal.pone.0241265 DOI: https://doi.org/10.1371/journal.pone.0241265
Guan W, Liang W, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with covid-19 in China: a nationwide analysis. Eur Respir J. [Internet]. 2020 may; 55(5): 2000547. Disponible en: https://erj.ersjournals.com/content/55/5/2000547 DOI: https://doi.org/10.1183/13993003.01227-2020
Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (covid-19). Respir Med. [Internet]. 2020 jun; 167: 105941. Disponible en: https://www.resmedjournal.com/article/S0954-6111(20)30081-0/fulltext DOI: https://doi.org/10.1016/j.rmed.2020.105941
Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med. [Internet]. 2020 abr; 8(5): 436-438. Disponible en: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30167-3/fulltext DOI: https://doi.org/10.1016/S2213-2600(20)30167-3
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). Global Initiative for Chronic Obstructive Lung Disease; 2020. Disponible en: https://goldcopd.org/wp-content/uploads/2019/11/GOLD2020-REPORT-ver1.0wms.pdf
Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. [Internet]. 1987 feb; 106(2): 196-204. Disponible en: https://www.acpjournals.org/doi/10.7326/0003-4819-106-2-196 DOI: https://doi.org/10.7326/0003-4819-106-2-196
Kurai D, Saraya T, Ishii H, Takizawa H. Virus-induced exacerbations in asthma and COPD. Front Microbiol. [Internet]. 2013 oct; 4: 293. Disponible en: https://www.frontiersin.org/articles/10.3389/fmicb.2013.00293/full DOI: https://doi.org/10.3389/fmicb.2013.00293
García-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population-based cohort study. Thorax. [Internet]. 2006 sept; 61(9): 772-778. Disponible en: https://thorax.bmj.com/content/61/9/772 DOI: https://doi.org/10.1136/thx.2006.060145
Soler-Cataluña JJ, Martínez-García M, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. [Internet]. 2005 nov; 60(11): 925-931. DOI: https://doi.org/10.1136/thx.2005.040527
Hewitt R, Farne H, Ritchie A, Luke E, Johnston S L, Mallia, P. The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. Ther Adv Respir Dis. [Internet]. 2016; 10(2): 158-174. DOI: https://doi.org/10.1177/1753465815618113
Anzueto A. Impact of exacerbations on COPD. EurRespir Rev. [Internet]. 2010 jun; 19(116): 113-118. Disponible en: https://err.ersjournals.com/content/19/116/113 DOI: https://doi.org/10.1183/09059180.00002610
Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. [Internet]. 2003 ago; 124(2): 459-67. Disponible en: https://journal.chestnet.org/article/S0012-3692(15)33325-0/fulltext DOI: https://doi.org/10.1378/chest.124.2.459
Kherad O, Kaiser L, Bridevaux PO, Sarasin F, Thomas Y, Janssens JP, et al. Upper-respiratory viral infection, biomarkers, and COPD exacerbations. Chest. [Internet]. 2010 oct; 138(4): 896-904. Disponible en: https://journal.chestnet.org/article/S0012-3692(10)60538-7/fulltext DOI: https://doi.org/10.1378/chest.09-2225
Spencer S, Jones P. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. [Internet]. 2003 jul; 58(7): 589-593. Disponible en: https://thorax.bmj.com/content/58/7/589 DOI: https://doi.org/10.1136/thorax.58.7.589
Perotin JM, Dury S, Renois F, Deslee G, Wolak A, Du- val V, et al. Detection of multiple viral and bacterial infections in acute exacerbation of chronic obstructive pulmonary disease: a pilot prospective study. J Med Virol. [Internet]. 2013 may; 85(5): 866-873. DOI: https://doi.org/10.1002/jmv.23495
Lawrence H, Hunter A, Murray R, Lim WS, McKeever T. Cigarette smoking and the occurrence of influenza - Systematic review. J Infect. [Internet]. 2019 nov; 79(5): 401-406. DOI: https://doi.org/10.1016/j.jinf.2019.08.014
Atto B, Eapen-Mathew S, Sharma P, Frey U., Ammit AJ, Markos J, et al. New therapeutic targets for the prevention of infectious acute exacerbations of COPD: role of epithelial adhesion molecules and inflammatory pathways. Clin Sci. [Internet]. 2019 jul133(14): 1663- 1703 DOI: https://doi.org/10.1042/CS20181009
Eapen MS, Sharma P, Moodley YP, Hansbro PM, Sohal SS. Dysfunctional immunity and microbial adhesion molecules in smoking-induced pneumonia. Am J Respir Crit Care Med. [Internet]. 2019 ene; 199(2): 250-251. DOI: https://doi.org/10.1164/rccm.201808-1553LE
Kurai D, Saraya T, Ishiiand H, Takizawa H. Virus-induced exacerbations in asthma and COPD. Front Microbiol. [Internet]. 2013 oct; 293(4). Disponible en: https://doi.org/10.3389/fmicb.2013.00293
Importancia de los virus en las exacerbaciones de Enfermedad Pulmonar Obstructiva Crónica (EPOC). ¿Podría cambiar su comportamiento durante la pandemia de SARS-COV-2 (COVID-19)? en: https://www.frontiersin.org/articles/10.3389/fmicb.2013.00293/full DOI: https://doi.org/10.3389/fmicb.2013.00293
Eapen MS, Sharma P, Sohal S. Mitochondrial dysfunction in macrophages: a key to defective bacterial phagocytosis in COPD. Eur Respir J. [Internet]. 2019 oct; 54(4): 1901641. Disponible en: https://erj.ersjournals.com/content/54/4/1901641 DOI: https://doi.org/10.1183/13993003.01641-2019
Eapen MS, Sohal SS. Understanding novel mechanisms of microbial pathogenesis in chronic lung disease: Implications for new therapeutic targets. Clin Sci (Lond). [Internet]. 2018 feb; 132(3): 375-379. Disponible en: https://portlandpress.com/clinsci/article-abstract/132/3/375/72102/Understanding-novel-mechanisms-of-microbial?redirectedFrom=fulltext DOI: https://doi.org/10.1042/CS20171261
Sohal SS. Inhaled corticosteroids and increased microbial load in COPD: Potential role of epithelial adhesion molecules. Eur Respir J. [Internet]. 2018 ene; 51(2): 1702257. Disponible en: https://erj.ersjournals.com/content/51/2/1702257 DOI: https://doi.org/10.1183/13993003.02257-2017
Han L, Ran J, Mak YW, Suen LK, Lee PH, Peiris JSM, et al.Smoking and influenza-associated morbidity and mortality: a systematic Review and meta-analysis. Epidemiology. [Internet]. 2019 may; 30(3): 405- 417. Disponible en: https://journals.lww.com/epidem/Abstract/2019/05000/Smoking_and_Influenza_associated_Morbidity_and.15.aspx DOI: https://doi.org/10.1097/EDE.0000000000000984
Mallia P, Message SD, Gielen V, Contoli M, Gray K, Kebadze T, et al.Experimental Rhinovirus Infection as a Human Model of Chronic Obstructive Pulmonary Disease Exacerbation. Am J Respir Crit Care Med. [Internet]. 2011 mar; 183(6): 734-742. Disponible en: https://www.atsjournals.org/doi/full/10.1164/rccm.201006-0833OC DOI: https://doi.org/10.1164/rccm.201006-0833OC
Wilkinson T, Donaldson G, Johnston S, Openshaw P, Wedzicha J. Respiratory syncytial virus, airway inflammation, and fev1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. [Internet]. 2006 abr; 173(8): 871-876. Disponible en: https://www.atsjournals.org/doi/full/10.1164/rccm.200509-1489OC DOI: https://doi.org/10.1164/rccm.200509-1489OC
Seemungal T, Harper-Owen R, Bhowmik A, Sanderson G, Message S, MacCallum P, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. [Internet]. 2001 nov; 164(9): 1618-1623. Disponible en: https://www. atsjournals.org/doi/full/10.1164/ajrccm.164.9.2105011 DOI: https://doi.org/10.1164/ajrccm.164.9.2105011
Papi A, Bellettato CA, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. [Internet]. 2006 may; 173(10): 1114-1121. DOI: https://doi.org/10.1164/rccm.200506-859OC
Frickmann H, Jungblut S, Hirche TO, Groß U, Kuhns M, Zautner AE. The influence of virus infections on the course of COPD. Eur J Microbiol Immunol. [Inter- net]. 2012 sept; 2(3): 176-185. Disponible en: https://akjournals.com/view/journals/1886/2/3/article-p176. xml DOI: https://doi.org/10.1556/EuJMI.2.2012.3.2
Peiris JSM, Chu CM, Cheng VCC, Chan KS, Hung IFN, Poon LLM, et al. Clinical progression and viral load in a community outbreak of coronavirus-associa- ted SARS pneumonia: a prospective study. Lancet. [Internet]. 2003 may; 361(9371): 1767-1772. DOI: https://doi.org/10.1016/S0140-6736(03)13412-5
Memish ZA, Perlman S, Van Kerkhove MD, Zumla A. Middle east respiratory syndrome. Lancet. [Internet]. 2020 mar; 395(10229): 1063-1077. Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)33221-0/fulltext DOI: https://doi.org/10.1016/S0140-6736(19)33221-0
Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Journal Emerging Microbes & Infections. [Internet]. 2020 dic; 9(1): 727-732. DOI: https://doi.org/10.1080/22221751.2020.1746199
Raj VS, Mou H, Smits SL, Dekkers DH, Müller MA, Dijkman R, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-emc. Nature. [Internet]. 2013 mar; 495(7440): 251-254. DOI: https://doi.org/10.1038/nature12005
Coutard B, Valle C, Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. [Internet]. 2020 abr; 176: 104742. DOI: https://doi.org/10.1016/j.antiviral.2020.104742
Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell rna expression profiling of ace2, the putative receptor of Wuhan 2019-nCov. Am J Respir Crit Care Med. [Internet]. 2020 sept; 202(5): 756-759. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462411/ DOI: https://doi.org/10.1164/rccm.202001-0179LE
Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking upregulates angiotensin - converting enzyme-2 receptor: a potential adhesion site for novel coronavirus SARS-CoV-2 (covid-19). J Clin Med. [Internet]. 2020 mar; 9(3); 841. DOI: https://doi.org/10.3390/jcm9030841
Singh AK, Gupta R, Misra A. Comorbidities in covid-19: outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr. [Internet]. 2020 ago; 14(4): 283- 287. Disponible en: https://www.sciencedirect.com/science/article/pii/S1871402120300564?via%3Dihub DOI: https://doi.org/10.1016/j.dsx.2020.03.016
Leung JM, Yang CX, Tam A, Shaipanich T, Hackett TL, Singhera GK, et al. ace-2 expression in the small airway epithelia of smokers and COPD patients: implications for covid-19. Eur Respir J. [Internet]. 2020 may; 55(5): 2000688. Disponible en: https://erj.ersjournals.com/content/55/5/2000688 DOI: https://doi.org/10.1183/13993003.00688-2020
Arnold F, Mahmood K, Angeline P, Aden D, Raghu- ram A, Burns MA, et al. COPD exacerbation caused by SARS-CoV-2: a case report from the Louisville covid-19 surveillance program. The Univ Louisville J Respir Infect. [Internet]. 2020; 4(1): artículo 5. Disponible en: https://ir.library.louisville.edu/jri/vol4/iss1/5/
Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. [Internet]. 2005 jul; 436(7047): 112-116. Disponible en: https://www.nature.com/articles/nature03712 DOI: https://doi.org/10.1038/nature03712
Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. [Internet]. 2020 may; 395(10235): 1517-1520. DOI: https://doi.org/10.1016/S0140-6736(20)30920-X
Jones PW, Lamarca R, Chuecos F, Singh D, Agustí A, Bateman ED, et al. Characterisation and impact of reported and unreported exacerbations: results from attain. Eur Resp J. [Internet]. 2014 nov; 44(5): 1156-1165. Disponible en: https://erj.ersjournals.com/content/44/5/1156 DOI: https://doi.org/10.1183/09031936.00038814
Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. [Internet]. 1998 may; 157(1): 1418-1422. Disponible en: https://www.atsjournals.org/doi/full/10.1164/ajrccm.157.5.9709032 DOI: https://doi.org/10.1164/ajrccm.157.5.9709032
Thomas Y, Boquete-Suter P, Koch D, Pittet D, Kaiser LL. Survival of influenza virus on human fingers. Clin Microbiol Infect. [Internet]. 2014 ene; 20(1): 92-93. Disponible en: https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(14)60219-6/fulltext DOI: https://doi.org/10.1111/1469-0691.12324
Kac G, Podglajen I, Gueneret M, Vaupre S, Bissery A, Meyer G. Microbiological evaluation of two hand hygiene procedures achieved by healthcare workers during routine patient care: a randomized study. J Hosp Infect. [Internet]. 2005 may; 60(1): 32-39. DOI: https://doi.org/10.1016/j.jhin.2004.10.014
Zhou SS, Lukula S, Chiossone C, Nims RW, Suchmann DB, Ijaz MK. Assessment of a respiratory face mask for capturing air pollutants and pathogens including human influenza and rhinoviruses. J Thorac Dis. [Internet]. 2018 mar 10(3): 2059- 2069. Disponible en: https://jtd.amegroups.com/article/view/20136/15564 DOI: https://doi.org/10.21037/jtd.2018.03.103
Ma QX, Shan H, Zhang HL, Li GM, Yang RM, Chen JM. Potential utilities of mask‐wearing and instant hand hygiene for fighting SARS-CoV-2. J Med Virol. [Internet]. 2020 sept; 92(9): 1567-1571. Disponible en: https://onlinelibrary.wiley.com/doi/10.1002/jmv.25805 DOI: https://doi.org/10.1002/jmv.25805
McManus TE, Coyle PV, Kidney JC. Childhood respiratory infections and hospital admissions for copd. Resp Med. [Internet]. 2006 mar; 100(3): 512-518. DOI: https://doi.org/10.1016/j.rmed.2005.06.001
Greenberg SB. Viral respiratory infections in elderly patients and patients with chronic obstructive pulmonary disease. Am J of Med. [Internet]. 2002 abr; 112(6): 28-32. DOI: https://doi.org/10.1016/S0002-9343(01)01061-0
Johnston SL, Pattemore PK, Sanderson G, Smith S, Campbell MJ, Josephs LK, et al. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med. [Internet]. 1996 sept; 154(3): 654-660. Disponible en: https://www.atsjournals.org/doi/abs/10.1164/ajrccm.154.3.8810601 DOI: https://doi.org/10.1164/ajrccm.154.3.8810601
Mannino D, Braman S. The epidemiology and economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc. [Internet]. 2007 oct; 4(7): 502- 506. Disponible en: https://pats.atsjournals.org/cgi/doi/10.1513/pats.200701-001FM DOI: https://doi.org/10.1513/pats.200701-001FM
Celli BR, MacNee W, Agusti A, Anzueto A, Berg B, Buist AS, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ats/ers position paper. Eur Respir J. [Internet]. 2004 jun; 23(6): 932-946. Disponible en: https://erj.ersjournals.com/content/23/6/932 DOI: https://doi.org/10.1183/09031936.04.00014304
Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD [Internet]. 2010 jun; 7(3): 214-28. Disponible en: https://www.tandfonline.com/doi/abs/10.3109/15412555.2010.481697?journalCode=icop20 DOI: https://doi.org/10.3109/15412555.2010.481697
Simoens S, Decramer M, De Coster S, Celis G, Laekeman G. Clinical and economic analysis of antimicrobial therapy of chronic obstructive pulmonary disease exacerbations. Int J Clin Pract. [Internet]. 2007 feb; 61(2): 200-206. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/j.1742-1241.2006.01240.x DOI: https://doi.org/10.1111/j.1742-1241.2006.01240.x
O'Reilly JF, Williams AE, Rice L. Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J Clin Pract. [Internet]. 2007 jul; 61(7): 1112-1120. DOI: https://doi.org/10.1111/j.1742-1241.2007.01424.x
Mittmann N, Kuramoto L, Seung SJ, Haddon JM, Bradley-Kennedy C, FitzGerald JM. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respir Med. [Internet]. 2008 mar; 102(3): 413-421. DOI: https://doi.org/10.1016/j.rmed.2007.10.010
Oostenbrink JB, Rutten-van-Molken MPM. Resource use and risk factors in high-cost exacerbations of COPD. Respir Med. [Internet]. 2004 sept; 98(9): 883-891. Disponible en: https://www.resmedjournal.com/article/S0954-6111(04)00082-4/fulltext DOI: https://doi.org/10.1016/j.rmed.2004.02.013
Copyright (c) 2022 Revista Med
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
